“The equity shares of Sanofi Consumer Healthcare India Ltd (Scrip Code: 544250) are listed and admitted to dealings on the Exchange in the list of ”T” Group Securities,” the company stated in an exchange filing.
Sanofi Consumer Healthcare India is the demerged consumer healthcare division of Sanofi India. The board of Sanofi India approved the demerger on May 10, 2023, separating the Consumer Healthcare business into a new entity, Sanofi Consumer Healthcare India Limited. This move is expected to unlock greater value and foster sustainable growth for the consumer healthcare segment.
Following the demerger, Sanofi retained a 60.4% stake in both entities, and shareholders received one Sanofi Consumer Healthcare India equity share of Rs 10 each for every equity share held.
The company’s top consumer healthcare brands include Allegra, DePURA, Avil, and Combiflam.
In contrast, shares of Sanofi India fell nearly 1% in early trade on BSE. Despite this, the stock has surged over 35% year-to-date and 53% over the past year.In Q1 of FY25, Sanofi India reported a 16% year-on-year (YoY) decline in net profit at Rs 103.2 crore. In the corresponding quarter, Sanofi India posted a net profit of Rs 123 crore.The company’s revenue from operations dipped 10% to Rs 463.5 crore against Rs 515 crore in the corresponding period of the preceding fiscal. At the operating level, EBITDA fell 4.8% to Rs 115.7 crore in the first quarter of this fiscal over Rs 121.5 crore in the year-ago period.
(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)